-- 根據週四提交給深圳證券交易所的文件，雲南白藥（SHE:000538）第一季歸屬於母公司股東的淨利潤年增5.3%，達到20.4億元人民幣，去年同期為19.3億元。 這家醫療產品製造商的每股盈餘較去年同期成長5.6%，達到1.14元人民幣，去年同期為1.08元。 營業收入較去年同期成長7%，達116億元人民幣，去年同期為108億元。
Related Articles
Australia
Amazon's Backlog Ramp Points to Accelerating Revenue Growth, UBS Says
Amazon's (AMZN) backlog ramp, including $100 billion from Anthropic, points to accelerating revenue growth in 2026 and 2027, UBS said in a Thursday report."While there may still be some variability on the magnitude, the backlog ramp continues to point the way to accelerating revenue growth throughout 2026 and 2027, which should in turn raise investor confidence on ROIC," the note said. ROIC refers to return on invested capital.For 2026, the base case for Amazon Web Services growth is now 36%, the report said, adding that consolidated near-term revenue estimates have also moved up, driven by the e-commerce business following Q1 beat.UBS reiterated its buy rating and boosted its price target to $333 from $304.Price: $259.19, Change: $-3.85, Percent Change: -1.46%
$AMZN
Australia
Wells Fargo Adjusts Price Target on CoStar Group to $33 From $40
CoStar Group (CSGP) has an average rating of overweight and mean price target of $50.33, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $34.15, Change: $+0.01, Percent Change: +0.03%
$CSGP
Australia
Morgan Stanley Adjusts Price Target on AbbVie to $278 From $270
AbbVie (ABBV) has an average rating of overweight and mean price target of $253.15, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $213.21, Change: $+9.32, Percent Change: +4.57%
$ABBV